Capital BlueCross Open/Closed Formulary Update (1 st Quarter 2017)
|
|
- Daniel Gardner
- 5 years ago
- Views:
Transcription
1 Capital BlueCross Open/Closed Formulary Update (1 st Quarter 2017) The Capital BlueCross formulary is a reference list of prescription drugs that contains a wide range of generic and brand drugs that have been approved by the U.S. Food and Drug Administration (FDA). The formulary is updated on a quarterly basis or when new generic or brand-name medications become available and as discontinued drugs are removed from the marketplace. Several new drugs have come to market and are now included in our formulary. KEY: Capital BlueCross Formulary Update lowercase print = generic; UPPERCASE PRINT = BRAND; (PAR) = Prior Authorization Required; (EPA) = Enhanced Prior Authorization Required; (QLL) = Quantity Level Limits Apply Brand Name CINRYZE* (PAR) VEMLIDY* Tier Status BNP BP Newly Marketed Drugs Effective Immediately Indication Prophylactic therapy for hereditary angioedema Treatment of chronic hepatitis B virus (HBV) infection in adults with compensated liver disease. KEY: Generic Preferred (GP), Generic Non-Preferred (GNP), Brand Preferred (BP), Brand Non-Preferred (BNP) Preferred Alternatives N/A entecavir, lamivudine The Capital BlueCross formulary serves as a reference for all prescription drug benefit designs ranging from an open formulary to a closed formulary. An open formulary provides access to generic preferred, generic non-preferred, brand preferred brand and brand non-preferred medications. A closed formulary provides access to generic preferred, generic non-preferred and brand preferred medications. Brand non-preferred medications are not covered under a closed formulary. You or your physician may request coverage for medically necessary brand non-preferred drugs through the Nonformulary Consideration Process. KEY: Capital BlueCross Formulary Update lowercase print = generic; UPPERCASE PRINT = BRAND; (PAR) = Prior Authorization Required; (EPA) = Enhanced Prior Authorization Required; (QLL) = Quantity Level Limits Apply Brand Name Products Changing Tier Status (Open/Closed) Current Tier (Open/Closed) New Tier Preferred Alternatives EPIPEN, EPIPEN JR. (PAR) BP BNP epinephrine pen
2 Certain medications are subject to Enhanced Prior Authorization (EPA) due to health care concerns and/or safety reasons. In order to have these medications covered under your prescription drug benefit, you may be required to try a formulary alternative first or to complete the Prior Authorization process. To obtain Prior Authorization, your physician or pharmacist should call or fax a request with supporting clinical information to the CVS/caremark TM Prior Authorization Department at (Fax: ). Members may initiate a Prior Authorization request by calling CVS/caremark at or by visiting the website at capbluecross.com. Certain medications are also subject to Quantity Level Limit (QLL) to help promote appropriate use of medications and enhance patient safety. Prescriptions written for more than the allowed quantity will only be filled up to the allowed amount. Your physician can direct quantity override requests to CVS/caremark by calling or faxing the request with supporting clinical information to (Fax: ). The following medications have been added to the Prior Authorization (PAR) program. KEY: Pharmacy Management Program Update (PAR) = Prior Authorization Required; (ST) = Step Therapy Required; (QLL) = Quantity Level Limits Apply lowercase print = generic; UPPERCASE PRINT = BRAND CINRYZE* (PAR) Prior Authorization (PAR) Program Effective Immediately Purpose/Guidelines Diagnosis of hereditary angioedema Pharmacy Management Program Update Prior Authorization (PAR) Program EPINEPHRINE AUTO INJECTORS (PAR) : ADRENACLICK, AUVI Q, EPIPEN, EPIPEN JR. Purpose/Guidelines Diagnosis of an anaphylactic reaction and trial and failure of generic epinephrine pen
3 Pharmacy Management Program Update Prior Authorization (PAR) Program Purpose/Guidelines OPIOID/EXTENDED RELEASE PRODUCTS (PAR,QLL) : ARYMO ER TABLET 15MG,30MG,60MG, AVINZA CAPSULE 30MG,45MG,60MG,75MG,90MG,120MG, BELBUCA FILM 75MCG,150MCG,300MCG,450MCG,600MCG,750MCG,900M CG, BUTRANS PATCH 5MCG,HR,7.5MCG/HR,10MCG/HR,20MCG/HR,15MCG/HR, CONZIP CAPSULE 100MG,200MG,300MG, DURAGESIC PATCH 12MCG/HR,25MCG/HR,50MCG/HR,75MCG/HR,100MCG/H, EMBEDA CAPSULE MG, MG,50-2MG,60-2.4MG,80-3.2MG,100-4MG,EXALGO TABLET 8MG,12MG,16MG,32MG, fentanyl patch 12mcg/hr,25mcg/hr,50mcg,75mcg/hr,100mcg/hr, FENTANYL PATCH 37.5MCG,62.5MCG,87.5MCG, hydromorphone tablet 8mg er,12mg er,16mg er,32mg er, HYSINGLA ER TABLET 20 MG,30 MG,40 MG,60 MG,80 MG,100 MG,120 MG,KADIAN CAPSULE 10MG ER,20MG ER,30MG ER,40MG ER,50MG ER,60MG ER,80MG ER,100MG ER,200MG ER, morphine sulfate beads capsule 24hr 30 mg sr,45 mg sr,60 mg sr,75 mg sr,90 mg sr,120 mg sr, morphine sulfate capsule 24hr 10 mg sr,20 mg sr, 30 mg sr, 50 mg sr,60 mg sr,80 mg sr,100 mg sr, morphine sulfate tablet 15mg er,30mg er,60mg er, 100mg er,200mg er, MS CONTIN TABLET 15MG ER,30MG ER,60MG ER,100MG ER,200MG ER, NUCYNTA ER TABLET 50MG,100MG,150MG,200MG,250MG, OPANA ER TABLET 5MG,7.5MG,10MG,15MG,20MG,30MG,40MG, oxycodone tablet 10mg er,20mg er,40mg er,60mg er,80mg er, OXYCONTIN ER TABLET 10MG,15MG,20MG,30MG,40MG,60MG,80MG, oxymorphone tablet 7.5mg er,5mg er,10mg er,15mg er,20mg er,30mg er,40mg er, tramadol biphasic tablet 100mg er,200mg er,300mg er, tramadol capsule 200mg er, 300mg er, TRAMADOL HCL CAPSULE 150MG ER, tramadol tablet 100mg er,200mg er,300mg er, ULTRAM ER TABLET 100MG, 200MG, 300MG, XTAMPZA ER CAPSULE 9MG,13.5MG,18MG,27MG,36MG, ZOHYDRO ER CAPSULE 10MG,15MG,20MG,30MG,40MG,50MG Diagnosis of pain related to a terminal diagnosis AND The requested doses do not exceed FDA or accepted clinical dosing guidelines AND Member does not have a contraindication to opioid therapy OR Diagnosis of severe chronic pain AND The requested doses do not exceed FDA or accepted clinical dosing guidelines AND Member does NOT have a contraindication to opioid therapy Member has a history of opioid use AND Member has been evaluated and will be monitored regularly for the development of opioid use disorder (abuse or dependence) AND Member s pain will be reassessed each month after the initial prescription
4 Pharmacy Management Program Update OPIOID ORAL/NASAL FENTANYL PRODUCTS (PAR,QLL) : ABSTRAL SUBLINGUAL 100 MCG,200 MCG,300 MCG,400 MCG,600 MCG,800 MCG, ACTIQ LOZENGE 200MCG,400MCG,600MCG,800MCG,1200MCG,1600MCG, fentanyl lozenge 200MCG,400MCG,600MCG,800MCG,1200MCG,1600MCG, FENTORA TABLET 100 MCG,200 MCG,400 MCG,600 MCG,800 MCG, LAZANDA SPRAY 100MCG,400MCG, SUBSYS SPRAY 100MCG,200MCG,400MCG,600MCG,800MCG, 1200MCG,1600MCG Prior Authorization (PAR) Program Purpose/Guidelines The patient does NOT have a contraindication to opioid therapy AND Member has Member has chronic pain related to cancer AND Fentanyl oral or intranasal is being used for breakthrough pain AND Member has a history of appropriate long acting opioids utilization OPIOID/METHADONE PRODUCTS (PAR,QLL) : DOLOPHINE TABLET 5MG,10MG,methadone tablet 5mg,10mg,methadone solution 5mg/5ml,10mg/5ml Diagnosis of chronic severe pain associated with a terminal diagnosis AND Member does not have a contraindication to opioid therapy AND OR Methadone is being prescribed for severe, persistent chronic pain AND Member does NOT have a contraindication to opioid therapy such as: Patient has been evaluated for at least TWO nonpharmacologic therapies Member s pain will be reassessed in the first month after the initial prescription or any dose increase AND every 3 months thereafter to ensure that clinically meaningful improvement in pain and function outweigh risks to patient safety
5 Pharmacy Management Program Update Prior Authorization (PAR) Program Purpose/Guidelines MEDICATION ASSISTED TREATMENTS (PAR,QLL) : BUNAVAIL FILM MG, MG,6.3-1MG, buprenorphine sublingual tab 2mg, 8mg, buprenorphine/naloxone sublingual tab 2-0.5mg,8-2mg, SUBOXONE FILM SUBLINGUAL 2-0.5MG,4-1MG,8-2MG,12-3MG, SUBOXONE SUBLINGUAL 2-0.5MG,8-2MG, ZUBSOLV SUBLINGUAL TAB MG, MG, MG, MG, MG, MG Member has a diagnosis of opioid dependence in patients 16 years of age or older; Prescriber has received a Drug Addiction Treatment Act (DATA) 2000 waiver The drug is being used as part of a complete program for the treatment of opioid dependence Prescriber has reviewed the Pennsylvania Prescription Drug Monitoring Program The following medications have been added to the Quantity Level Limit (QLL) program. Pharmacy Management Program Update Quantity Level Limit (QLL) Program OPIOID IMMEDIATE RELEASE COMBINATION PRODUCTS acetaminophen/codeine solution mg/5ml (QLL) acetaminophen/codeine tablet 2 (300-15mg),3 (300mg- 30mg), 4 (300mg-60mg) (QLL) acetaminophen-caffeine-dihydrocodeine capsule mg (QLL) ACETAMINOPHEN-CAFFEINE-DIHYDROCODEINE TABLET MG (QLL) aspirin-caffeine-dihydrocodeine capsule mg (QLL) CAPITAL/CODEINE SUSPENSION MG/5ML (QLL) endocet tablet mg (QLL) endocet tablet mg,5-325mg (QLL) 630 ml 70 cap 70 tab 70 cap 630 ml
6 Pharmacy Management Program Update Quantity Level Limit (QLL) Program OPIOID IMMEDIATE RELEASE COMBINATION PRODUCTS endocet tablet mg (QLL) endodan tablet (QLL) HYCET SOLUTION MG,15 ml (QLL) hydrocodone/ibuprofen tablet mg,5-200mg, mg,10-200mg (QLL) hydrocodone-acetaminophen solution , mg/15ml (QLL) hydrocodone-acetaminophen tablet mg, mg, mg,10-325mg (QLL) hydrocodone-acetaminophen tablet mg (QLL) hydrocodone-acetaminophen tablet 5-300mg,5-325mg (QLL) ibudone tablet 5-200mg,10-200mg (QLL) lorcet hd tablet mg (QLL) lorcet plus tablet mg (QLL) lorcet tablet 5-325mg (QLL) LORTAB ELIXIR MG/15 ml (QLL) lortab tablet mg, mg (QLL) lortab tablet 5-325mg (QLL) NORCO TABLET MG, MG (QLL) NORCO TABLET 5-325MG (QLL) oxycodone w/ acetaminophen soln mg/5ml (QLL) 630 ml 35 tab 630 ml 35 tab 473 ml 140 ml oxycodone/acetaminophen tablet mg (QLL) oxycodone/acetaminophen tablet mg, 5-325mg (QLL)
7 Pharmacy Management Program Update Quantity Level Limit (QLL) Program OPIOID IMMEDIATE RELEASE COMBINATION PRODUCTS oxycodone/acetaminophen tablet mg (QLL) oxycodone/aspirin tablet mg (QLL) oxycodone/ibuprofen tablet 5-400mg (QLL) PERCOCET TABLET MG (QLL) PERCOCET TABLET MG, 5-325MG (QLL) PERCOCET TABLET MG (QLL) PERCODAN TABLET MG (QLL) PRIMLEV TABLET MG (QLL) PRIMLEV TABLET 5-300MG (QLL) PRIMLEV TABLET MG (QLL) reprexain tablet mg (QLL) REPREXAIN TABLET MG, 5-200MG (QLL) ROXICET SOLUTION 5-325MG/5ML (QLL) roxicet tablet 5-325mg (QLL) SYNALGOS-DC CAPSULE MG (QLL) tramadol-acetaminophen tablet mg (QLL) TREZIX CAPSULE MG (QLL) TYLENOL/CODEINE TABLET 3, 4 (QLL) ULTRACET TABLET MG (QLL) verdrocet tablet mg (QLL) vicodin es tablet mg (QLL) 35 tab 35 tab 140 ml 70 cap 70 cap
8 Pharmacy Management Program Update Quantity Level Limit (QLL) Program OPIOID IMMEDIATE RELEASE COMBINATION PRODUCTS vicodin hp tablet mg(QLL) vicodin tablet 5-300mg (QLL) VICOPROFEN TABLET MG (QLL) XARTEMIS XR TABLET MG (QLL) XODOL TABLET MG, MG (QLL) XODOL TABLET 5-300MG (QLL) xylon tablet mg (QLL) zamicet solution mg/15 ml (QLL) 35 tab 35 tab 630 ml OPIOID IMMEDIATE RELEASE SINGLE PRODUCTS butorphanol nasal spray 10mg/ml (QLL) CODEINE SULFATE SOLUTION 15MG/2.5ML, 30MG/5ML (QLL) codeine sulfate tablet 15 mg,30mg, 60mg (QLL) CODEINE SULFATE TABLET 60 MG (QLL) DEMEROL TABLET 50MG,100MG (QLL) DILAUDID LIQUID 1MG/ML (QLL) DILAUDID TABLET 2MG,4MG,8MG (QLL) hydromorphone liquid 1mg/ml (QLL) hydromorphone suppository (QLL) HYDROMORPHONE SUPPOSITORY 3MG (QLL) hydromorphone tablet 2mg,4mg,8mg (QLL) levorphanol tablet 2mg (QLL) 5 ml (2 bottles) 210 ml 18 tab 140 ml 140 ml 28 supp 28 supp
9 OPIOID IMMEDIATE RELEASE SINGLE PRODUCTS meperidine solution 50mg/5ml (QLL) meperidine syrup 50mg/5ml (QLL) meperidine tablet 50mg/100mg (QLL) morphine sulfate solution 10mg/0.5ml,20mg/ml,100mg/5ml (QLL) morphine sulfate solution 10mg/5ml (QLL) morphine sulfate solution 20mg/5ml (QLL) morphine sulfate suppository 5mg,10mg (QLL) morphine sulfate suppository 20mg (QLL) MORPHINE SULFATE SUPPOSITORY 30MG (QLL) morphine sulfate suppository 30mg (QLL) morphine sulfate tablet 15mg (QLL) morphine sulfate tablet 30mg (QLL) msir solution 10mg/5ml (QLL) msir solution 20mg/5ml (QLL) NUCYNTA TABLET 100MG (QLL) NUCYNTA TABLET 50MG (QLL) NUCYNTA TABLET 75MG (QLL) OPANA TABLET 10MG (QLL) OPANA TABLET 5MG (QLL) OXAYDO TABLET 5MG,7.5MG (QLL) oxycodone capsule 5mg (QLL) oxycodone concentrate 10mg/0.5ml,20mg/ml,100mg/5ml (QLL) oxycodone solution 5mg/5ml (QLL) OXYCODONE TABLET 10MG (QLL) 90 ml 90 ml 18 tab 32 ml 210 ml 158 ml 42 supp 28 supp 21 supp 21 supp 21 tab 210 ml 158 ml 14 tab 21 tab 21 tab 42 cap 30 ml 420 ml
10 OPIOID IMMEDIATE RELEASE SINGLE PRODUCTS oxycodone tablet 5mg,10mg (QLL) oxycodone tablet 15mg (QLL) OXYCODONE TABLET 20MG (QLL) oxycodone tablet 20mg (QLL) oxycodone tablet 30mg (QLL) oxycodone tablet er 10mg,15mg,20mg,30mg,40mg,60mg,80mg (QLL) oxymorphone hcl tablet 10mg (QLL) oxymorphone hcl tablet 5mg (QLL) pentazocine/naloxone tablet mg (QLL) percolone tablet 5mg (QLL) ROXICODONE TABLET 15MG (QLL) ROXICODONE TABLET 30MG (QLL) ROXICODONE TABLET 5MG (QLL) tramadol hcl tablet 50mg (QLL) ULTRAM TABLET 50MG (QLL) 21 tab 21 tab 14 tab 21 tab 14 tab OPIOID EXTENDED RELEASE PRODUCTS ARYMO ER TABLET 15MG, 30MG, 60MG (PAR,QLL) AVINZA CAPSULE 30MG, 45MG, 60MG, 75MG,90MG, 120MG (PAR,QLL) BELBUCA FILM 75MCG, 150MCG, 300MCG, 450MCG, 600MCG, 750MCG, 900MCG (PAR,QLL) BUTRANS PATCH 5MCG/HR, 7.5MCG/HR 10MCG/HR, 15MCG/HR, 20MCG/HR (PAR,QLL) CONZIP CAPSULE 100MG, 200MG, 300MG (PAR,QLL) DURAGESIC PATCH 12MCG/HR, 25MCG/HR 100MCG/HR, 50MCG/HR, 75MCG/HR (PAR,QLL) EMBEDA CAPSULE MG, MG, 50-2MG, MG, MG, 100-4MG (PAR,QLL) EXALGO TABLET 8MG,12MG,16MG,32MG (PAR,QLL) 60 film 4 patch 10 patch
11 OPIOID EXTENDED RELEASE PRODUCTS fentanyl patch 12mcg/hr,25mcg/hr,50mcg,75mcg/hr,100mcg/hr (PAR,QLL) FENTANYL PATCH 37.5MCG,62.5MCG,87.5MCG (PAR,QLL) hydromorphone tablet 8mg er,12mg er,16mg er,32mg er (PAR,QLL) HYSINGLA ER TABLET 20 MG,30 MG,40 MG,60 MG,80 MG,100 MG,120 MG (PAR,QLL) KADIAN CAPSULE 10MG ER,20MG ER,30MG ER,40MG ER, 50MG ER,60MG ER,80MG ER,100MG ER,200MG ER (PAR,QLL) morphine sulfate beads capsule sr 24hr 30mg,45mg,60mg,75mg,90mg,120 mg (PAR,QLL) morphine sulfate capsule sr 24hr 10 mg,20 mg,30 mg,50 mg,60 mg,80 mg,100 mg (PAR,QLL) morphine sulfate tablet 15mg er,30mg er,60mg er,100mg er,200mg er (PAR,QLL) MS CONTIN TABLET 15MG ER,30MG ER,60MG ER, 100MG ER,200MG ER (PAR,QLL) NUCYNTA ER TABLET 50MG,100MG,150MG,200MG, 250MG (PAR,QLL) OPANA ER TABLET 5MG,7.5MG,10MG,15MG,20MG,30MG,40MG (PAR,QLL) oxycodone tablet 10mg er,20mg er,40mg er,60mg er,80mg er (PAR,QLL) OXYCONTIN ER TABLET 10MG,15MG,20MG,30MG,40MG,60MG,80MG (PAR,QLL) oxymorphone tablet 5mg er,7.5mg er,10mg er,15mg er,20mg er,30mg er,40mg er (PAR,QLL) tramadol biphasic tablet 100mg er,200mg er,300mg er (PAR,QLL) tramadol capsule 200mg er,300mg er (PAR,QLL) TRAMADOL HCL CAPSULE 150MG ER (PAR,QLL) tramadol tablet 100mg er,200mg er,300mg er (PAR,QLL) 10 patch 10 patch ULTRAM ER TABLET 100MG, 200MG,300MG (PAR,QLL) XTAMPZA ER CAPSULE 9MG,13.5MG,18MG,27MG,36MG (PAR,QLL) ZOHYDRO ER CAPSULE 10MG,15MG,20MG,30MG,40MG,50MG (PAR,QLL) ABSTRAL SUBLINGUAL 100 MCG,200 MCG,300 MCG,400 MCG,600 MCG,800 MCG (PAR,QLL) FENTANYL PRODUCTS (ORAL/INTRANASAL) 60 cap 60 cap 120 subl tab
12 FENTANYL PRODUCTS (ORAL/INTRANASAL) ACTIQ LOZENGE 200MCG,400MCG,600MCG,800MCG,1200MCG,1600MCG (PAR,QLL) fentanyl lozenge 200MCG,400MCG,600MCG,800MCG,1200MCG,1600 (PAR,QLL) FENTORA TABLET 100 MCG,200 MCG,400 MCG,600 MCG,800 MCG (PAR,QLL) LAZANDA SPRAY 100MCG,400MCG (PAR,QLL) SUBSYS SPRAY 100MCG,200MCG,400MCG,600MCG,800MCG (PAR,QLL) SUBSYS SPRAY 1200MCG,1600MCG (PAR,QLL) 120 lozenge 120 lozenge 120 tab 30 sprays 120 sprays 240 sprays METHADONE PRODUCTS DOLOPHINE TABLET 5MG,10MG (PAR,QLL) methadone tablet 5mg,10mg (PAR,QLL) methadone solution 5mg/5ml,10mg/5ml (PAR,QLL) 300 ml MEDICATION ASSISTED TREATMENTS BUNAVAIL FILM MG, MG,6.3-1MG (PAR,QLL) buprenorphine sublingual 2mg (PAR,QLL) buprenorphine sublingual 8mg (PAR,QLL) buprenorphine/naloxone sublingual 2-0.5mg,8-2mg (PAR,QLL) SUBOXONE FILM SUBLINGUAL 2-0.5MG,4-1MG,8-2MG (PAR,QLL) SUBOXONE FILM SUBLINGUAL12-3MG (PAR,QLL) ZUBSOLV SUBLINGUAL MG, MG, MG, MG (PAR,QLL) ZUBSOLV SUBLINGUAL MG (PAR,QLL) ZUBSOLV SUBLINGUAL MG (PAR,QLL) 60 film 240 tab 90 tab 90 film 60 film 90 tab
Opioid Management Program October 2018
Opioid Management Program October 2018 What Is the Opioid Management Program? This program is based on guidelines developed by the U.S. Centers for Disease Control and Prevention (CDC). It consists of
More informationOpioid Management Program May 2018
Opioid Management Program May 2018 What Is the Opioid Management Program? This program is based on guidelines developed by the U.S. Centers for Disease Control and Prevention (CDC). It consists of daily
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Controlled Substance Analgesic and Narcotic Antagonist Quantity Limitations Table of Contents Coverage Policy... 1 General Background... 6 Coding/Billing
More informationGeneric Label Name Drug Strength Dosage Form Example Product (s) MME/Unit ACETAMINOPHEN WITH CODEINE
STATE OF TENNESSEE DEPARTMENT OF FINANCE AND ADMINISTRATION DIVISION OF HEALTH CARE FINANCE AND ADMINISTRATION BUREAU OF TENNCARE 3 Great Circle Road NASHVILLE, TENNESSEE 37243 This notice is to advise
More informationOpioid Analgesic/Opioid Combination Products
Market DC Opioid Analgesic/Opioid Combination Products Override(s) Quantity Limit Approval Duration 1 year Generic Name Brand Name Quantity Limit APAP/Caf/Dihydrocodeine 320.5mg/30mg/16mg APAP/Caf/Dihydrocodeine
More informationAPPROVED PA CRITERIA. Initial Approval: January 10, 2018 Revised Dates: April 11, 2018 CRITERIA FOR PRIOR AUTHORIZATION
Initial Approval: January 10, 2018 Revised Dates: April 11, 2018 CRITERIA FOR PRIOR AUTHORIZATION PROVIDER GROUP Pharmacy Opioid Products Indicated for Pain Management MANUAL GUIDELINES All dosage forms
More informationPequot Health Care Opioid Analgesic Quantity Program*
Pequot Health Care 1 Annie George Drive Mashantucket, CT 06338 Phone: 1-888-779-6638 Fax: 1-860-396-6494 Pequot Health Care Opioid Analgesic Quantity Program* Effective January 2018 *Quantity Program limits
More informationOpioid Analgesic/Opioid Combination Products
Opioid Analgesic/Opioid Combination Products Override(s) Quantity Limit Approval Duration 1 year Generic Name Brand Name Quantity Limit 320.5mg/30mg/16mg 356.4mg/30mg/16mg 325mg/30mg/16mg Trezix (new formulation)
More informationPrior Authorization Opioid Overutilization 2017
Drugs Requiring Prior Authorization Label Name ACETAMINOPHEN/CAFFEINE/DIHYDROCODEINE CAPSULE ACETAMINOPHEN/CODEINE SOLUTION ACETAMINOPHEN/CODEINE TABLET ASCOMP/CODEINE CAPSULE BUTALBITAL/CAFFEINE/ACETAMINOPHEN/CODEINE
More informationXyrem (Sodium Oxybate)
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Clinical Criteria Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Opioid Immediate Release Page 1 of 13 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Opioid Immediate Release Prime Therapeutics will review Prior Authorization
More informationCarefirst. +.V Family of health care plans
Family of health care plans Prior Authorization Form 1361M Opioids ER MME Limit and Post Limit This fax machine is located in a secure location as required by HPAA regulations. Complete/review information,
More informationPharmacy Medical Necessity Guidelines: Opioid Analgesics
Pharmacy Medical Necessity Guidelines: Effective: January 1, 2019 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED) Benefit
More informationOpiate/Benzodiazepine/Muscle Relaxant Combinations
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Opiate/Benzodiazepine/Muscle Relaxant Combinations Clinical Edit Information Included in this Document Drugs requiring prior authorization:
More informationNew Hampshire Healthy Families CLINICAL POLICY
New Hampshire Healthy Families CLINICAL POLICY DEPARTMENT: Pharmacy DOCUMENT NAME: Opioid Analgesics PAGE: 1 o f 6 REFERENCE NUMBER: NH.PPA.13 EFFECTIVE DATE: 6/1/2016 REPLACES DOCUMENT: N/A RETIRED: REVIEWED:
More information: Opioid Quantity Limits
March 7, 2017 2017-09: Opioid Quantity Limits The Louisiana Department of Health (LDH), in conjunction with the Louisiana Medicaid Drug Utilization Review (DUR) Board, has revised quantity limits for selected
More informationPRESCRIPTION DRUG PROGRAM FORMULARY UPDATES Select Formulary October 1, 2018 Updates. Formulary. Alternatives
PRESCRIPTION DRUG PROGRAM FORMULARY UPDATES Select October 1, 2018 Updates Drug Name efavirenz 600mg (Brand = Sustiva ) trientine (Brand = Syprine ) hydrocortisone lot 0.1% (Brand = Locoid ) sumatriptan-naproxen
More informationTexas Prior Authorization Program Clinical Edit Criteria
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
More informationMEDICARE Program Policies & Procedures POLICY NUMBER: Medicare D-111
POLICY: Medicare Part D Formulary-Level Cumulative Opioid and Opioid/Buprenorphine POS Edits MEDICARE Program Policies & Procedures POLICY NUMBER: Medicare D-111 Policy for contracts H3351, S3521 and H3335
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Opioid Therapy Table of Contents Coverage Policy... 1 General Background... 4 Coding/Billing Information... 7 References... 7 Effective Date..1/1/2018 Next
More informationLong-Acting Opioid Analgesics
Market DC Long-Acting Opioid Analgesics Override(s) Prior Authorization Step Therapy Quantity Limit Approval Duration Initial request: 3 months Maintenance Therapy: Additional prior authorization required
More informationLong-Acting Opioid Analgesics
Market DC Long-Acting Opioid Analgesics Override(s) Prior Authorization Step Therapy Quantity Limit Approval Duration Initial request: 3 months Maintenance Therapy: Additional prior authorization required
More information20/0.8mg, 30/1.2mg, Films 90 MME/day Belbuca (buprenorphine) 75mcg, 150mcg, 300mcg, 450mcg 60 units per 90 days
Pre - PA Allowance Quantity Extended Release Tablets or Capsules 90 MME/day Medication Strength Avinza (morphine) 60mg, 75mg, 90mg Embeda (morphine /naltrexone) 50/2mg, 60/2.4mg, 80/3.2mg Exalgo (hydromorphone)
More informationPrior Authorization Guideline
Guideline GL-35952 Opioid Quantity Limit Overrides Formulary OptumRx Formulary Note: Approval Date 7/10/2017 Revision Date 7/10/2017 Technician Note: P&T Approval Date: 2/16/2010; P&T Revision Date: 7/12/2011
More informationDrug Name (specify drug) Quantity Frequency Strength
Prior Authorization Form GEHA FEDERAL - STANDARD OPTION 1363-M Opioids IR MME Limit and Post Limit This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More informationPrior Authorization for Opioid Products Indicated for Pain Management
Kansas Medical Assistance Program PA Phone 800-933-6593 PA Fax 800-913-2229 Amerigroup PA Pharmacy Phone 855-201-7170 PA Pharmacy Fax 800-601-4829 Sunflower PA Pharmacy Phone 877-397-9526 PA Pharmacy Fax
More informationDrug Name (specify drug) Quantity Frequency Strength
Prior Authorization Form MEDICA HEALTH PLAN IA EXCHANGE 1362-M Opioids IR Labeling Post Limit (HMF) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More informationMedication Policy Manual. Topic: Immediate-release (IR) Opioid Medication Products for Pain. Date of Origin: January 1, 2018
Independent licensees of the Blue Cross and Blue Shield Association Medication Policy Manual Topic: Immediate-release (IR) Opioid Medication Products for Pain Policy No: dru516 Date of Origin: January
More informationOpioids, Extended Release (ER) Quantity Limit Criteria Program Summary
Opioids, Extended Release (ER) Quantity Limit Criteria Program Summary This program applies to Commercial, GenPlus, NetResults A series, Netresults F series and Health Insurance Marketplace. Belbuca is
More information** Fee-For-Service Pharmacy Provider Notice #229 May 2018 PDL Changes **
** Fee-For-Service Pharmacy Provider Notice #229 May 2018 PDL Changes ** August 03, 2018 Please be advised that the Department for Medicaid Services (DMS) is making changes to the Kentucky Medicaid Fee-For-Service
More informationQUANTITY LIMIT AND POST LIMIT PRIOR AUTHORIZATION CRITERIA
DRUG CLASS QUANTITY LIMIT AND POST LIMIT PRIOR AUTHORIZATION CRITERIA EXTENDED-RELEASE OPIOID ANALGESICS BRAND NAME (generic) ARYMO ER (morphine sulfate extended-release tablets) AVINZA (morphine extended-release
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Opioids, Extended Release (ER) Page 1 of 12 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Opioids, Extended Release (ER) Prime Therapeutics will review Prior Authorization
More informationPRESCRIPTION DRUG LIST CHANGES
PRESCRIPTION DRUG LIST CHANGES Cigna Pharmacy Management The medications listed below are changing coverage (or cost levels) on Cigna s Prescription Drug List. Changes are listed by drug list and by the
More informationMorphine Sulfate Hydromorphone Oxymorphone
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.02.33 Subject: Morphine Drug Class Page: 1 of 8 Last Review Date: June 19, 2015 Morphine Sulfate Hydromorphone
More informationOpioid Analgesics. Recommended starting dose for opioid-naïve patients
Opioid Analgesics Goals: Restrict use of opioid analgesics to OHP-funded conditions with documented sustained improvement in pain and function and with routine monitoring for opioid misuse and abuse. Promote
More informationDemystifying Opioid Conversion Calculations
Demystifying Opioid Conversion Calculations Stephanie Cheng, PharmD, MPH, BCGP Clinical Pharmacist Hospice Pharmacy Solutions November 28, 2018 Learning Objectives After this presentation, you should be
More informationDisposal of Unused Medicines: What You Should Know
1 of 8 3/12/16 11:14 PM U.S. Food and Drug Administration Protecting and Promoting Your Health Disposal of Unused Medicines: What You Should Know Topics on this page Overview List of Medicines Recommended
More informationPharmacy Management Drug Policy
SUBJECT: Opioid Management Health and Safety Program POLICY NUMBER: PHARMACY-34 EFFECTIVE DATE: 6/2007 LAST REVIEW DATE: 07/01/2018 If the member s subscriber contract excludes coverage for a specific
More informationPAIN. TREATMENT TABLES Analgesics. NON-OPIOID ANALGESICS Generic Name Trade Names (Examples) Duration Initial Dose
NON-OPIOID SHORT-ACTING LONG-ACTING **** O PAIN TREATMENT TABLES Analgesics NON-OPIOID ANALGESICS Generic Name Trade Names (Examples) Duration Initial Dose Tramadol 50 mg Ultram Every 4 hours 1-2 tabs,
More informationDisposal of Unused Medicines: What You Should Know
1 of 8 04/27/2016 1:37 AM U.S. Food and Drug Administration Protecting and Promoting Your Health Disposal of Unused Medicines: What You Should Know Topics on this page (http://www.fda.gov/aboutfda/aboutthiswebsite
More informationLong-Acting Opioid. Policy Number: Last Review: 12/2017 Origination: 09/2013 Next Review: 09/2018
Long-Acting Opioid Policy Number: 5.02.519 Last Review: 12/2017 Origination: 09/2013 Next Review: 09/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for long-acting
More informationHow To Green My Pharmacy. Prepared and presented by Luna El Bizri,Pharm-D, Community Pharmacist
How To Green My Pharmacy Prepared and presented by Luna El Bizri,Pharm-D, Community Pharmacist Learning Objectives At the end of this presentation, pharmacists will be able to : 1. Understand the negative
More informationFuture Formulary Changes
Future Formulary Changes Upd 09/11/2018 Applies to: Employer group plan 2018 open formularies KEY: =prior authorization; ST=step therapy; QL=quantity limit Generic name Brand name Change Effective Hydroxyprogesterone
More informationADDITIONAL 2017 FORMULARY CHANGES CIGNA COMMERCIAL CUSTOMERS
ADDITIONAL 2017 FORMULARY CHANGES CIGNA COMMERCIAL CUSTOMERS Effective 7/1/2017, Cigna will be making additional formulary changes that may impact customers at your pharmacy. We have included a list of
More informationMedication Policy Manual. Date of Origin: January 1, Topic: Extended-release (ER) Opioid Medication Products for Pain
Medication Policy Manual Topic: Extendedrelease (ER) Opioid Medication Products for Pain Policy No: dru515 Date of Origin: January 1, 2018 Committee Approval Date: January 19. 2018 Next Review Date: December
More informationSTEP THERAPY WITH QUANTITY LIMIT AND POST LIMIT PRIOR AUTHORIZATION CRITERIA. AVINZA (morphine extended-release capsules)
Carelirst. +.V Family of health care plans cvs caremarktm STEP THERAPY WITH QUANTITY LIMIT AND POST LIMIT PRIOR AUTHORIZATION CRITERIA DRUG CLASS EXTENDED-RELEASE OPIOID ANALGESICS BRAND NAME* (generic)
More informationLimitations of use: Subsys may be dispensed only to patients enrolled in the TIRF REMS Access program (1).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.21 Subject: Subsys Page: 1 of 5 Last Review Date March 17, 2017 Subsys Description Subsys (fentanyl
More informationMedication Policy Manual. Topic: Extended-release (ER) Opioid Medication Products for Pain. Date of Origin: January 1, 2018
Independent licensees of the Blue Cross and Blue Shield Association Medication Policy Manual Topic: Extended-release (ER) Opioid Medication Products for Pain Policy No: dru515 Date of Origin: January 1,
More informationEmbeda. Embeda (morphine sulfate and naltrexone hydrochloride) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.39 Subject: Embeda Page: 1 of 6 Last Review Date: March 18, 2016 Embeda Description Embeda (morphine
More informationEquianalgesic Dosing of Opioids for Pain Management
PL Detail-Document #300405 This PL Detail-Document accompanies the related article published in PHARMACIST S LETTER / PRESCRIBER S LETTER April 2014 Equianalgesic Dosing of Opioids for Pain Management
More information``Considerations for using opioid drug therapy in workers compensation include patient safety, drug effectiveness and financial impacts
Opioids Effective Case Management Opioids RELEVANCE IN WORKERS COMP Opioids are a diverse group of drugs that represent the strongest pain medications available. They are frequently prescribed for pain
More informationCHANGES TO YOUR DRUG LIST
CHANGES TO YOUR DRUG LIST More generics and lower-cost brands to help you stay healthy and save money At Cigna, it s our goal to offer you access to coverage for safe, effective and affordable medications.
More information10 mg hydrocodone equals how much oxycodone
Cari untuk: Cari Cari 10 mg hydrocodone equals how much oxycodone Posts about dilaudid 8 vs oxycodone 30 written by buyprescriptionmedication. Can you help me with the conversion of Oxycodone IR (5mg tab)
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 3053-9 Program Step Therapy Long Acting Opioids Medication Includes both brand and generic versions of the listed products unless
More informationBeneficiary Advisory Panel Handout Uniform Formulary Decisions 24 June 2010
Beneficiary Advisory Panel Handout Uniform Formulary Decisions 24 June 2010 PURPOSE: The purpose of this handout is to provide BAP Committee members with a reference document for the relative clinical
More information15 mg morphine 10 mg hydrocodone
Cari untuk: Cari Cari 15 mg morphine 10 mg hydrocodone 3-2-2013 Convert From CALCULATED MORPHINE EQUIVALENT BY RESOURCE: Average ( mg ) Range ( mg ) Standard Deviation of Sample ( mg ) Hydrocodone. I usually
More informationDemerol (meperidine oral tablet, oral solution), Meperitab (oral tablet)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subsection: Analgesics and Opioids Original Policy Date: May 8, 2015 Subject: Meperidine Page: 1 of 5 Last
More informationDrug Use Evaluation: Short Acting Opioids (SAO)
Drug Use Evaluation: Short Acting Opioids (SAO) Summary Short acting opioid analgesics are one of the most prescribed (top 10) and highest cost (top 20) medication classes for the Oregon Fee For Service
More informationPRESCRIPTION DRUG PROGRAM FORMULARY UPDATES Select Formulary April 1, 2018 Updates. Formulary Alternatives
PRESCRIPTION DRUG PROGRAM FORMULARY UPDATES Select April 1, 2018 Updates Drug Name adapalene-benzoyl-peroxide Gel 0.1-2.5% (Brand = Epiduo ) prasugrel hcl (Brand = Effient ) vigabatrin pak 500 mg (Brand
More informationPRESCRIPTION DRUG BENEFITS. open/closed formulary. Capital BlueCross is an Independent Licensee of the BlueCross BlueShield Association
GUIDE TO PRESCRIPTION DRUG BENEFITS open/closed formulary Capital BlueCross is an Independent Licensee of the BlueCross BlueShield Association TABLE OF CONTENTS 2 Contact Us Phone Number Website 3 Using
More informationAddressing Drug Diversion
Webinar Objectives Addressing Drug Diversion Bernice Burkarth, MD, HMDC, FAAHPM BBurkarth@treasurehealth.org October12, 2017 At the completion of this Webinar, participants will be able to: Identify tools
More informationImmediate Release Opioid Analgesics (Brand and Generic): Acute Pain Duration Limit with MME Limit and Post Limit Policy
BENEFIT APPLICATION DRUG POLICY Immediate Release Opioid Analgesics (Brand and Generic): Acute Pain Duration Limit with MME Limit and Post Limit Policy Benefit determinations are based on the applicable
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.CPA.259 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory
More informationAETNA BETTER HEALTH Prior Authorization guideline for Narcotic Analgesic Utilization
AETNA BETTER HEALTH Prior Authorization guideline for Narcotic Analgesic Utilization Policy applies to all formulary and non-formulary schedules II V opioid narcotics, including tramadol and codeine, as
More informationDisposal by Flushing of Certain Unused Medicines: What
Disposal by Flushing of Certain Unused Medicines: What You Should Know Drugs Page 1 of 5 Disposal by Flushing of Certain Unused Medicines: What You Should Know Overview Frequently Asked Questions List
More informationDuragesic patch. Duragesic patch (fentanyl patch) Description
1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.31 Subject: Duragesic patch Page: 1 of 6 Last Review Date: March 18, 2016 Duragesic patch Description Duragesic patch (fentanyl
More informationPRESCRIPTION DRUG PROGRAM FORMULARY UPDATES Select Formulary April 1, 2018 Updates. Formulary Alternatives
PRESCRIPTION DRUG PROGRAM FORMULARY UPDATES Select April 1, 2018 Updates Drug Name adapalene-benzoyl-peroxide Gel 0.1-2.5% (Brand = Epiduo ) prasugrel hcl (Brand = Effient ) vigabatrin pak 500 mg (Brand
More informationOpioid Capture in the AHSQC Can we reduce use by measuring it? Michael Reinhorn MD, MBA, FACS Dept of Surgery, Newton Wellesley Hospital
Opioid Capture in the AHSQC Can we reduce use by measuring it? Michael Reinhorn MD, MBA, FACS Dept of Surgery, Newton Wellesley Hospital Disclosure Davol/Bard Consultant Medtronic Physician Advisory Honorarium
More information1/29/2013. Schedule II Controlled Substances: Basics and Beyond. Controlled Substances. Controlled Substances, Schedule I
chedule II Controlled ubstances: Basics and Beyond James L. Besier, Ph.D., R.Ph., FAHP Adjunct Associate Professor College of Nursing Adjunct Assistant Professor James L. Winkle College of Pharmacy University
More informationADDITIONAL 2017 FORMULARY CHANGES CIGNA COMMERCIAL CUSTOMERS
ADDITIONAL 2017 FORMULARY CHANGES CIGNA COMMERCIAL CUSTOMERS Cigna will be making additional formulary changes that may impact customers at your pharmacy. We have included a list of drugs by drug class
More informationEXTENDED RELEASE OPIOID DRUGS
RATIONALE FOR INCLUSION IN PA PROGRAM Background Hydrocodone (Hysingla ER, Vantrela ER, Zohydro ER), hydromorphone (Exalgo), morphine sulfate (Arymo ER, Avinza, Embeda, Kadian, MorphaBond, MS Contin),
More information2019 LIST OF COVERED DRUGS (FORMULARY)
2019 LIST OF COVERED DRUGS (FORMULARY) Prescription drug list information UnitedHealthcare Connected for MyCare Ohio (Medicare-Medicaid Plan) Toll-free 1-877-542-9236, TTY 711 8 a.m. - 8 p.m. local time,
More informationSession II. Learning Objectives for Session II. Key Principles of Safe Prescribing. Benefits and Limitations of ER/LA Opioids
Learning Objectives for Session II Session II Best Practices for How to Start Therapy with ER/LA Opioids, How to Stop, and What to Do in Between Upon completion of this module, the participants will be
More informationOpioid Analgesic Treatment Worksheet
Opioid Analgesic Treatment Worksheet Aetna Better Health of Louisiana Fax: 1 844 699 2889 www.aetnabetterhealth.com/louisiana/providers/pharmacy LA Legacy Fee for Service (FFS) Medicaid Fax: 1 866 797
More information2014 FORMULARY LIST OF COVERED DRUGS
PLEASE READ: This formulary was updated on January 1, 2014. For more recent information or other questions, please contact Viva Medicare Member Services at 1-800-633-1542 or, for TTY users, 711, Monday
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 3053-7 Program Step Therapy Long Acting Opioids Medication Includes both brand and generic versions of the listed products unless
More informationFORMULARY LIST OF COVERED DRUGS
FORMULARY LIST OF COVERED DRUGS 2018 PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION ABOUT THE DRUGS WE COVER IN THIS PLAN. HPMS Approved Formulary File Submission ID 00018248, Version Number #3 This formulary
More informationMethadone. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.41 Subject: Methadone Page: 1 of 8 Last Review Date: March 18, 2016 Methadone Description Dolophine
More informationDURATION LIMIT CRITERIA ACETAMINOPHEN/ASPIRIN/IBUPROFEN CONTAINING OPIOID ANALGESICS (BRAND AND GENERIC) (acetaminophen and benzhydrocodone)
Carelirst. +.V Family of health care plans cvs caremarktm DRUG CLASS (generic)* DURATION LIMIT CRITERIA ACETAMINOPHEN/ASPIRIN/IBUPROFEN CONTAINING OPIOID ANALGESICS (BRAND AND GENERIC) (acetaminophen and
More informationMorphine Equivalent Dosing
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class This criteria was recommended for review by the Texas Medicaid Vendor Drug Program to ensure appropriate and safe utilization. Clinical
More informationDURATION LIMIT WITH QUANTITY LIMIT AND POST LIMIT PRIOR AUTHORIZATION CRITERIA IMMEDIATE-RELEASE OPIOID ANALGESICS (BRAND AND GENERIC)*
Carelirst. +.V Family of health care plans cvs caremarktm DURATION LIMIT WITH QUANTITY LIMIT AND POST LIMIT PRIOR AUTHORIZATION CRITERIA DRUG CLASS generic name, dosage form IMMEDIATE-RELEASE OPIOID ANALGESICS
More informationFuture Formulary Changes
Future Formulary Changes Upd 11/21/2018 Applies to: Employer group plan 2018 2019 open formularies KEY: PA=prior authorization; ST=step therapy; QL=quantity limit Generic name Brand name Change Effective
More informationCommittee Approval Date: September 12, 2014 Next Review Date: September 2015
Medication Policy Manual Topic: fentanyl-containing medications: - Actiq, fentanyl citrate oral transmucosal lozenges - Abstral fentanyl sublingual tablets - Fentora, fentanyl buccal tablet - fentanyl
More informationAcetaminophen/Aspirin/Ibuprofen Containing Immediate Release Opioid Analgesics: Quantity Limit Policy
DRUG POLICY Acetaminophen/Aspirin/Ibuprofen Containing Immediate Release Opioid Analgesics: Quantity Limit Policy BENEFIT APPLICATION Benefit determinations are based on the applicable contract language
More informationBree Collaborative AMDG Opioid Prescribing Guidelines Workgroup. Opioid Prescribing Metrics - DRAFT
Bree Collaborative AMDG Opioid Prescribing Guidelines Workgroup Opioid Prescribing Metrics - DRAFT Definitions: Days Supply: The total of all opioid prescriptions dispensed during the calendar quarter
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 4000-3 Program Opioid Overutilization Cumulative Drug Utilization Review Criteria Medication Includes all salt forms, single and
More informationThe original MED criteria can be referenced at the Texas Vendor Drug Program website located at
Morphine Equivalent Dosing (MED) Clinical Edit Criteria Drug/Drug Class Morphine Equivalent Dosing (MED) Superior HealthPlan follows the guidance of the Texas Vendor Drug Program (VDP) for all clinical
More informationNATL. II. Health Net Approved Indications and Usage Guidelines: Diagnosis of cancer AND. Member is on fentanyl transdermal patches AND
Coverage of drugs is first determined by the member s pharmacy or medical benefit. Please consult with or refer to the Evidence of Coverage document I. FDA Approved Indications: The management of breakthrough
More informationNucynta IR/ Nucynta ER (tapentadol immediate-release and extendedrelease)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Nucynta Page: 1 of 7 Last Review Date: March 18, 2016 Nucynta Description Nucynta IR/ Nucynta
More informationcomprehensive formulary (list of covered drugs) January 1st - December 31st leon cares medicare
comprehensive formulary (list of covered drugs) leon cares 2019 medicare January 1st - December 31st PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION ABOUT THE DRUGS WE COVER IN THIS PLAN. Formulary ID
More informationTransmucosal Immediate Release Fentanyl (TIRF) Prior Authorization, (Through Generic), and Quantity Limit Program Summary
Transmucosal Immediate Release Fentanyl (TIRF) Prior Authorization, (Through Generic), and Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1-5 Drug Indication Dosage Abstral (fentanyl sublingual
More informationExtended Release Opioid Drugs
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Section: Prescription Drugs Effective Date: January 1, 2019 Subject: Extended Release Opioid Drugs Page:
More informationOpioid Analgesic Treatment Worksheet
Opioid Analgesic Treatment Worksheet Aetna Better Health of Louisiana Fax: 1 844 699 2889 www.aetnabetterhealth.com/louisiana/providers/pharmacy LA Legacy Fee for Service (FFS) Medicaid Fax: 1 866 797
More informationPercocet 10 without acetaminophen
Percocet 10 without acetaminophen Gogamz Menu Best Deals percocet without the acetaminophen. Low Cost. Pill Shop, Cheap Prices. Free samples for all orders. percocet without the acetaminophen. Learn about
More informationProposed Changes to Existing Measure for HEDIS : Use of Opioids at High Dosage (UOD)
Proposed Changes to Existing Measure for HEDIS 1 2020: Use of Opioids at High Dosage (UOD) NCQA seeks comments on proposed revisions to the Use of Opioids at High Dosage HEDIS measure. The current measure
More informationOPIOID IDENTIFICATION GUIDE
OPIOID IDENTIFICATION GUIDE WHAT ARE OPIOIDS, PRESCRIPTION PAINKILLERS, OR NARCOTICS? Rx Rx Rx Rx The Prescription Playbook Rx The Prescription Playbook is an education and awareness campaign for parents
More informationTechnician Training Tutorial: Safety Considerations with Opioids
(Page 1 of 5) Technician Training Tutorial: Safety Considerations with Opioids Opioids as a drug class are considered to be high-alert drugs. This class includes codeine, methadone, oxycodone, etc. When
More information